Leiner’s U.S. OTC Operations Face Regulatory, Competitive Obstacles
This article was originally published in The Tan Sheet
Executive Summary
Leiner Health Products says the process of restarting its U.S. OTC operations is complicated by Dr. Reddy's Laboratories' termination of contracts to supply ingredients it needs to manufacture OTCs
You may also be interested in...
Leiner’s Return To U.S. OTC Market Complicated By FDA Warning, DOJ Inquiry
FDA's investigation into manufacturing and quality control issues at Leiner Health Products' South Carolina facility revealed a culture of mismanagement that created a pattern of undetected production errors and overlooked discrepancies regarding product development, according to the agency
Leiner’s Return To U.S. OTC Market Complicated By FDA Warning, DOJ Inquiry
FDA's investigation into manufacturing and quality control issues at Leiner Health Products' South Carolina facility revealed a culture of mismanagement that created a pattern of undetected production errors and overlooked discrepancies regarding product development, according to the agency
Leiner’s Return To U.S. OTC Market Complicated By FDA Warning, DOJ Inquiry
FDA's investigation into manufacturing and quality control issues at Leiner Health Products' South Carolina facility revealed a culture of mismanagement that created a pattern of undetected production errors and overlooked discrepancies regarding product development, according to the agency